Drug intelligence / Profile preview

NCX 139

Development stage: Unknown
Lead developer: NicOx
Modality: Small Molecules

Overview

NCX 139 is a nitric oxide (NO)-donating derivative compound developed by Nicox. Specific details on the molecular structure, mechanism of action, and clinical development status of NCX 139 are not disclosed in the accessible scientific literature. Based on naming conventions and similarities to other Nicox pipeline agents, NCX 139 is likely a small molecule with an NO-donor mechanism developed for ophthalmologic or vascular indications, but definitive data are lacking.

Brand names: NCX 139NCX139NCX-139
Other names: NCX 139NCX139NCX-139

Beyond the preview

Go deeper on NCX 139.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NCX 139.

Explore the full profile